4//SEC Filing
DENYES NANCY 4
Accession 0001209191-20-032794
CIK 0001339970other
Filed
May 27, 8:00 PM ET
Accepted
May 28, 8:26 PM ET
Size
11.8 KB
Accession
0001209191-20-032794
Insider Transaction Report
Form 4
aTYR PHARMA INCLIFE
DENYES NANCY
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2020-05-16+892→ 3,057 total - Award
Employee Stock Option (right to buy)
2020-05-26+30,000→ 30,000 totalExercise: $4.06Exp: 2030-05-26→ Common Stock (30,000 underlying) - Exercise/Conversion
Restricted Stock Unit
2020-05-16−892→ 0 total→ Common Stock (892 underlying) - Sale
Common Stock
2020-05-20$3.62/sh−322$1,166→ 2,735 total
Footnotes (5)
- [F1]Restricted stock units (RSU) convert into common stock on a one-for-one basis.
- [F2]Includes 178 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 15, 2020.
- [F3]Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on May 16, 2018.
- [F4]50% of the shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 26, 2020, such that these shares will be fully exercisable on May 26, 2024; 25% of the shares subject to this option will vest on May 26, 2021 if and only if a clinical development milestone is achieved by September 30, 2020; and the remaining 25% of the shares will vest on May 26, 2021 if and only if an additional clinical development milestone is achieved by September 30, 2020.
- [F5]The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on May 16, 2019.
Documents
Issuer
aTYR PHARMA INC
CIK 0001339970
Entity typeother
Related Parties
1- filerCIK 0001640869
Filing Metadata
- Form type
- 4
- Filed
- May 27, 8:00 PM ET
- Accepted
- May 28, 8:26 PM ET
- Size
- 11.8 KB